Revumenib (SNDX-5613)
Relapsed/Refractory KMT2A-rearranged (KMT2Ar) Acute Leukemia
Key Facts
About Syndax Pharmaceuticals
Syndax Pharmaceuticals is a public biotech company pioneering novel cancer treatments by targeting key biological pathways, including the menin-KMT2A interaction and CSF-1R signaling. Its most advanced assets, revumenib and axatilimab, are in late-stage development for acute leukemias and chronic graft-versus-host disease, respectively, representing significant market opportunities. The company leverages a deep understanding of transcriptional regulation and the tumor microenvironment to develop differentiated therapies for patients with limited treatment options.
View full company profileAbout Syndax Pharmaceuticals
Syndax Pharmaceuticals is a public biotech company pioneering novel cancer treatments by targeting key biological pathways, including the menin-KMT2A interaction and CSF-1R signaling. Its most advanced assets, revumenib and axatilimab, are in late-stage development for acute leukemias and chronic graft-versus-host disease, respectively, representing significant market opportunities. The company leverages a deep understanding of transcriptional regulation and the tumor microenvironment to develop differentiated therapies for patients with limited treatment options.
View full company profile